Portland-Area Biotech Araceli Biosciences Closes $4.5 Million Round, Using Human-Cell Technology to Replace Animal Testing
Araceli Biosciences, a biotechnology company based in Tigard, Oregon, announced on November 12 that investor Jeff Swickard has joined its recently closed $4.5 million funding round. The company said the financing will support record commercial momentum: revenue in 2026 is expected to reach six times the level of two years ago.
Araceli develops high-performance cell-imaging platforms for new drug research. Its flagship Endeavor platform combines AI analysis software that lets researchers watch how human cells respond to drug candidates, producing earlier and more accurate data and reducing reliance on animal testing. The approach is known as New Approach Methodologies (NAMs) — using human-cell assays instead of animal models to verify drug safety and efficacy. The company says its platform has been adopted by 10 of the world's top 20 pharmaceutical companies, with business spanning the Bay Area, Boston, London and Berlin.
Swickard said the investment backs an Oregon innovator and a future in which science becomes smarter, faster and more humane. Araceli was founded in 2020 and spun out of Phoseon Technology in 2023; it has about 30 employees, most at its Tigard headquarters. The company says it is entering a second commercial phase, launching consumable products that work with its platform, with a larger rollout planned for 2027.
Source: PR Newswire
Published by GSM · USA (original Chinese edition)
Photo: 图：生物技术实验室（资料图）。图片来源：Wikimedia Commons，Ishtiaquebioinfo 摄，CC BY-SA 4.0。 Image: A biotechnology laboratory (file photo). Source: Wikimedia Commons, photo by Ishtiaquebioinfo, CC BY-SA 4.0.
